HIF1A and Rare hereditary hemochromatosis: DFO, which is clinically used as an iron chelator for treatment of patients with iron overload disease, inhibits the activity of prolyl hydroxylase, suppresses the transcriptional activity of HIF-1α and stabilizes HIF-1α [14].